Belite Bio, Inc BLTE
Set alert
154.74 USD +4.46 +2.97%
At close · Oct 30
154.74 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
146.90 Day range 156.33
98.10 52-week range 193.61
- YTD
- -3.26%
- 1 year
- +57.74%
- Open
- 148.79
- Prev close
- 150.28
- Mkt cap
- 6.23B
- Vol
- 234.88K
- Avg vol
- 177.42K
- EPS
- -2.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 146.90
- High
- 156.33
- Forward P/E
- 68.52
- Beta
- -1.23
- Short ratio
- 7.77
- Inst. own
- 24.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 161.62
- 200-d avg
- 160.36
- 1y target
- 228.89
1m chart
Built from the cached one-day intraday bars.
Signals (29)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 3:58 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:57 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:54 PM | 2 days ago |
| RSI: Overbought | Oct 30, 3:54 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 3:52 PM | 2 days ago |
| RSI: Overbought | Oct 30, 3:45 PM | 2 days ago |
| RSI: Overbought | Oct 30, 3:37 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:35 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:29 PM | 2 days ago |
| RSI: Overbought | Oct 30, 3:23 PM | 2 days ago |
| RSI: Overbought | Oct 30, 3:18 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:58 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:47 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:36 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:22 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:41 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:36 PM | 2 days ago |
| RSI: Overbought | Oct 30, 1:21 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:18 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:16 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:48 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:48 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:01 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:44 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:39 AM | 2 days ago |
Key statistics
- Market cap
- 6.24B
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 68.52
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 8.03
- EPS (TTM)
- -2.74
- Beta
- -1.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -22.10%
- Shares outstanding
- 40.27M
- Short % of float
- 6.03%
- 50-day average
- 161.62
- 200-day average
- 160.36
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 228.89 +47.9% upside
Now 154.74
- Target (low)
- 185.00
- Target (mean)
- 228.89
- Target (high)
- 303.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy2
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.76875.
Financials — quick view
BLTE Revenue — quarterly 0
BLTE Net income — quarterly -25.32M
BLTE EPS — quarterly -0.71
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.78627 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.73 | -0.70 | +0.03 | +4.11% |
| May 20, 2026 | Mar 31, 2026 | -0.60 | -0.34 | +0.26 | +43.33% |
| Mar 2, 2026 | Dec 31, 2025 | -0.56 | -0.38 | +0.18 | +32.14% |
| Nov 10, 2025 | Sep 30, 2025 | -0.53 | -0.65 | -0.12 | -22.64% |
| Aug 11, 2025 | Jun 30, 2025 | -0.47 | -0.50 | -0.03 | -6.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 9, 2026 | Mizuho | main | Outperform | Outperform |
| Sep 8, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 4, 2026 | Canaccord Genuity | init | — | Buy |
| Aug 14, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 14, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- belitebio.com
News
- Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19
- Belite Bio Announces Uplisting to the Nasdaq Global Select Market
- Belite Bio Files Marketing Authorization Application In Singapore, U.K., Switzerland For Tinlarebant To Treat Stargardt Disease Type 1
- Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
- Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
- Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
- Belite Bio, Inc. Sponsored ADR $BLTE Shares Sold by Squarepoint Ops LLC
- Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross
- Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234
Your note
Sign in to keep a note on BLTE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHEN WAN-SHAN | Director | Sale | Apr 8, 2026 | 9,096 |
| CHUANG HAO-YUAN | Chief Financial Officer | Sale | Sep 7, 2026 | 26,038 |
| LIN YU-HSIN | Chief Executive Officer | Sale | Sep 7, 2026 | 70,134 |
| MATA NATHAN L. | Officer | Sale | May 6, 2026 | 0 |
| SCHOLL HENDRIK PETER | Officer | Sale | Sep 30, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | 7.64% | 3,077,219 | 476.51M | Jun 29, 2026 |
| Paradigm Biocapital Advisors LP | 3.06% | 1,232,877 | 190.91M | Jun 29, 2026 |
| RTW Investments LP | 1.78% | 715,332 | 110.77M | Jun 29, 2026 |
| Millennium Management Llc | 1.23% | 494,564 | 76.58M | Jun 29, 2026 |
| Maverick Capital Ltd. | 0.98% | 396,311 | 61.37M | Jun 29, 2026 |
| Eventide Asset Management LLC | 0.97% | 390,829 | 60.52M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 0.97% | 390,829 | 60.52M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.20% | 80,462 | 12.46M | Jun 29, 2026 |
| SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Emerging Markets ETF | 0.07% | 30,052 | 4.65M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.02% | 6,727 | 1.04M | Aug 30, 2026 |
| T. ROWE PRICE Eqy. SERIES, INC.-T. Rowe Price Health Sciences PORT. | 0.01% | 5,400 | 836.19K | Jun 29, 2026 |
| Fidelity Concord Street Trust-Fidelity ZERO International Index Fund | 0.01% | 5,934 | 918.88K | Aug 30, 2026 |